Literature DB >> 29414150

Hypo-fractionated stereotactic radiotherapy of five fractions with linear accelerator for vestibular schwannomas: A systematic review and meta-analysis.

Thien Nguyen1, Courtney Duong2, John P Sheppard1, Seung Jin Lee1, Amar U Kishan3, Percy Lee3, Stephen Tenn4, Robert Chin4, Tania B Kaprealian5, Isaac Yang6.   

Abstract

Vestibular schwannomas (VS) are benign tumors stemming from the eighth cranial nerve. Treatment options for VS include conservative management, microsurgery, stereotactic radiosurgery, and fractionated radiotherapy. Though microsurgery has been the standard of care for larger lesions, hypo-fractionated stereotactic radiotherapy (hypo-FSRT) is an emerging modality. However, its clinical efficacy and safety have yet to be established. We conducted a systematic review and meta-analysis of manuscripts indexed in PubMed, Scopus, Web of Science, Embase, and Cochrane databases reporting outcomes of VS cases treated with hypo-FSRT. Five studies representing a total of 228 patients were identified. Across studies, the pooled rates of tumor control, hearing, facial nerve, and trigeminal nerve preservation were 95%, 37%, 97%, and 98%. No instances of malignant induction were observed at median follow-up of 34.8 months. Complications included trigeminal neuropathy (n = 3), maxillary paresthesia (n = 1), neuralgia (n = 1), vestibular dysfunction (n = 1), radionecrosis (n = 1), and hydrocephalus (n = 1). Hypo-FSRT may be another useful approach to manage VS, but studies with extended follow-up times are required to establish long-term safety.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Acoustic neuroma; Fractionated stereotactic radiosurgery; Radiotherapy; Vestibular schwannoma

Mesh:

Year:  2018        PMID: 29414150     DOI: 10.1016/j.clineuro.2018.01.005

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  7 in total

1.  Five-year outcomes following hypofractionated stereotactic radiotherapy delivered in five fractions for acoustic neuromas: the mean cochlear dose may impact hearing preservation.

Authors:  Zhiping Chen; Keiichi Takehana; Takashi Mizowaki; Megumi Uto; Kengo Ogura; Katsuyuki Sakanaka; Yoshiki Arakawa; Yohei Mineharu; Yuki Miyabe; Nobutaka Mukumoto; Susumu Miyamoto; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2018-03-19       Impact factor: 3.402

2.  LINAC-based stereotactic radiosurgery versus hypofractionated stereotactic radiotherapy delivered in 3 or 5 fractions for vestibular schwannomas: comparative assessment from a single institution.

Authors:  Linn Söderlund Diaz; Andreas Hallqvist
Journal:  J Neurooncol       Date:  2020-02-08       Impact factor: 4.130

Review 3.  Assessing the long-term safety and efficacy of gamma knife and linear accelerator radiosurgery for vestibular schwannoma: A systematic review and meta-analysis.

Authors:  Sergio W Guadix; Alice J Tao; Anjile An; Michelle Demetres; Umberto Tosi; Swathi Chidambaram; Jonathan P S Knisely; Rohan Ramakrishna; Susan C Pannullo
Journal:  Neurooncol Pract       Date:  2021-08-13

4.  Vestibular Schwannoma: Results of Hypofractionated Stereotactic Radiation Therapy.

Authors:  Pierre-Marie Pialat; Maxime Fieux; Stéphane Tringali; Guillaume Beldjoudi; Pascal Pommier; Ronan Tanguy
Journal:  Adv Radiat Oncol       Date:  2021-03-23

5.  Stereotactic radiosurgery and fractionated stereotactic radiosurgery for vestibular schwannomas: A comparison of clinical outcomes from the RSSearch patient registry.

Authors:  Raj Singh; Hayden Ansinelli; Jan Jenkins; Joanne Davis; Sanjeev Sharma; John Austin Vargo
Journal:  J Radiosurg SBRT       Date:  2019

Review 6.  Review: Neurological Complications From Therapies for Pediatric Brain Tumors.

Authors:  Thien Nguyen; Sabine Mueller; Fatema Malbari
Journal:  Front Oncol       Date:  2022-04-11       Impact factor: 5.738

Review 7.  Efficacy and comorbidities of hypofractionated and single-dose radiosurgery for vestibular schwannomas: a systematic review and meta-analysis.

Authors:  Umberto Tosi; Sergio Guadix; Anjile An; Drew Wright; Paul J Christos; Susan Pannullo; Andrew Brandmaier; Jonathan P S Knisely; Philip E Stieg; Rohan Ramakrishna
Journal:  Neurooncol Pract       Date:  2021-02-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.